Director Exits Cancer Drug Co. Following Farallon Pressure
Oncology medicine company Exelixis announced Monday that Lance Willsey will leave its board of directors following a campaign for his replacement by activist investor Farallon....To view the full article, register now.
Already a subscriber? Click here to view full article